orlistat
Selected indexed studies
- Orlistat-associated adverse effects and drug interactions: a critical review. (Drug Saf, 2008) [PMID:18095746]
- Orlistat, a new lipase inhibitor for the management of obesity. (Pharmacotherapy, 2000) [PMID:10730683]
- Orlistat. (Heart Dis, 2000) [PMID:11728255]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Orlistat-associated adverse effects and drug interactions: a critical review. (2008) pubmed
- Orlistat, a new lipase inhibitor for the management of obesity. (2000) pubmed
- Orlistat. (2000) pubmed
- Orlistat facilitates immunotherapy via AKT-FOXO3a-FOXM1-mediated PD-L1 suppression. (2025) pubmed
- Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer. (2022) pubmed
- Orlistat. (1998) pubmed
- Treatment of obesity and metabolic-associated fatty liver disease with a diet or orlistat: A randomized controlled trial. (2023) pubmed
- Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. (1998) pubmed
- Orlistat in the treatment of obesity. (2000) pubmed
- XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. (2004) pubmed